Loading organizations...
Founded in 2018 by clinician researchers Michael Fishman and Jason Pope, Celeri Health is a Wilmington, Delaware enterprise developing specialized software platforms designed for pain management and patient outcomes assessment. Under the strategic leadership of Chief Executive Officer Jon Brilliant, the company utilizes National Institutes of Health PROMIS tools to systematically evaluate patient experiences through its proprietary PainIntel and PainRWD analytics systems. Operating on a SaaS business model, the organization licenses its clinical technology to healthcare providers, medical device manufacturers, and pharmaceutical companies to deliver valuable insights. The digital platform is currently utilized by 120 medical providers operating across 12 states to gather clinical evidence and conduct standardized opioid risk screenings across seven pain dimensions. Supported by more than two million dollars in total venture funding, the business maintains a workforce of 13 employees to help improve patient care.
Celeri Health has raised $2.0M across 1 funding round.
Celeri Health has raised $2.0M in total across 1 funding round.
Celéri Health is a technology company specializing in transforming pain management through data-driven solutions. It builds a proprietary platform that collects and analyzes real-world patient-reported outcomes (PROs) and clinical data to improve chronic pain treatment. The platform serves healthcare providers, researchers, payers, and life sciences companies by enabling real-time, FDA-compliant clinical studies and generating actionable insights to optimize therapies and reduce opioid reliance. Its products, such as PainIntel and PainRWD, support pain measurement, analytics, and research data management, addressing the inadequacies of traditional pain scales and enabling personalized care. The company has gained traction with about 120 healthcare providers across 12 states and collaborates on clinical studies involving advanced medical devices like Medtronic’s Intellis Spinal Cord Stimulation system[1][2][3][4].
Founded in 2018 in Wilmington, Delaware, Celéri Health was co-founded by Dr. Michael Fishman and Dr. Jason Pope, both practicing pain specialists who recognized the limitations of the conventional zero-to-10 pain scale. Motivated by the need for more nuanced, patient-centered pain measurement, they developed the Real World Outcomes Platform to gather comprehensive, multidimensional pain data grounded in NIH metrics. Early pivotal moments include launching clinical studies and integrating their platform with implantable devices to track patient function and pain relief in real time. The leadership team also includes experienced technology executives like David (CTO) and healthcare strategists such as Cam and Kyle, who bring expertise in healthcare innovation, operational excellence, and consultative selling to physicians[1][5].
Celéri Health rides the growing trend of leveraging real-world data (RWD) and real-world evidence (RWE) to improve healthcare outcomes, particularly in chronic pain management where traditional clinical trials and pain metrics fall short. The timing is critical as the healthcare industry seeks alternatives to opioid treatments amid an ongoing epidemic and regulatory pressure. Market forces favor technologies that enable personalized medicine, value-based care, and faster drug/device development cycles. By providing a platform that integrates clinical care with research and regulatory needs, Celéri Health influences the ecosystem by accelerating evidence generation, supporting innovative therapies, and improving patient quality of life through data-driven insights[1][4][6].
Looking ahead, Celéri Health is poised to expand its platform capabilities, deepen partnerships with medtech and pharma companies, and broaden its clinical study portfolio, including upcoming brain wave activity research. Trends such as digital therapeutics, remote patient monitoring, and AI-driven analytics will shape its evolution. As healthcare increasingly embraces real-world evidence for regulatory and reimbursement decisions, Celéri’s influence is likely to grow, positioning it as a key enabler of personalized pain management and innovative clinical research. Its commitment to replacing outdated pain metrics with multidimensional, patient-centered data sets a new standard for the field and promises to transform chronic pain care globally[1][2][4].
Celeri Health has raised $2.0M in total across 1 funding round.
Celeri Health's investors include Iaso Ventures.
Celeri Health has raised $2.0M across 1 funding round. Most recently, it raised $2.0M Seed in April 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Apr 1, 2021 | $2M Seed | — | Iaso Ventures | Announced |
